Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

A single site, double-blinded, randomized controlled trial for postmenopausal women with urinary frequency, urgency, nocturia with or without urgency urinary incontinence symptoms. Patient's will be randomized between 0.01% vaginal estradiol cream with placebo oral pill or daily 50 milligrams oral Mirabegron with a placebo vaginal cream for 12 weeks.

NCT Number	NCT05221021
Lead Sponsor	Walter Reed National Military Medical Center
Conditions	Overactive Bladder Syndrome
Enrollment	152 participants
Start Date	2022-10-01
Primary Completion	2026-12-30 (estimated)
Study Completion	2027-01-30 (estimated)
Updated on ClinicalTrials.gov	2024-08-19